GAMMA Investing
CADL icon

GAMMA Investing’s Candel Therapeutics CADL Stock Holding History

GAMMA Investing’s Portfolio CADL Stock Details CADL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$20.9K Buy
2,003
+1,187
+145% +$13.2K ﹤0.01% 2923
2026
Q2 		$8.4K Buy
816
+567
+228% +$4.28K ﹤0.01% 3289
2026
Q1 		$1.22K Sell
249
-46
-16% -$250 ﹤0.01% 3796
2025
Q4 		$1.67K Buy
295
+96
+48% +$516 ﹤0.01% 3659
2025
Q3 		$1.02K Buy
199
+166
+503% +$959 ﹤0.01% 3610
2025
Q2 		$167 Sell
33
-153
-82% -$787 ﹤0.01% 3730
2025
Q1 		$1.05K Buy
186
+122
+191% +$997 ﹤0.01% 3550
2024
Q4 		$556 Buy
64
+35
+121% +$207 ﹤0.01% 3558
2024
Q3 		$201 Buy
+29
New +$180 ﹤0.01% 3498

Other funds holding CADL

Tanager Wealth Management
Tanager Wealth Management Goring On Thames, United Kingdom $1.2B AUM 12% 1-Year Est. Return
Tema ETFs
Tema ETFs New York $2.69B AUM 42.96% 1-Year Est. Return
Davenport & Co
Davenport & Co Richmond, Virginia $19.9B AUM 12.67% 1-Year Est. Return
Farther Finance Advisors
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
Nisa Investment Advisors
Nisa Investment Advisors St. Louis, Missouri $34.7B AUM 25.93% 1-Year Est. Return
EP
Essential Partners Rancho Santa Fe, California $219M AUM 37.92% 1-Year Est. Return

GAMMA Investing's CADL Position: Q3 2026 in Review

GAMMA Investing increased its Candel Therapeutics (CADL) stake by 145% in Q3 2026, buying an estimated $13.2K and bringing the position to 2,003 shares worth $20.9K. The position accounts for ﹤0.01% of the portfolio, ranked #2923.

GAMMA Investing first reported a position in CADL in Q3 2024 and has held it in 9 quarters since. 7 funds tracked by Wall St. Rank hold CADL as of Q3 2026.

  • GAMMA Investing held 2,003 shares of Candel Therapeutics worth $20.9K as of Q3 2026.
  • GAMMA Investing bought 1,187 Candel Therapeutics shares in Q3 2026, an estimated $13.2K.
  • Candel Therapeutics made up ﹤0.01% of GAMMA Investing's portfolio in Q3 2026, its #2923 holding.
  • GAMMA Investing first reported a position in Candel Therapeutics in Q3 2024 and has held it in 9 quarters since.
  • 7 funds tracked by Wall St. Rank held Candel Therapeutics as of Q3 2026.

Based on GAMMA Investing's 13F filing for Q3 2026, filed 8 Oct 2026.